Objective:In this study,we aim to enhance the anti-prostate cancer efficacy of cabazitaxel(CTX)and reduce its immunosuppression and systemic toxicity by developing CTX-loaded liposomes modified with ginsenoside Rk1(Rk...Objective:In this study,we aim to enhance the anti-prostate cancer efficacy of cabazitaxel(CTX)and reduce its immunosuppression and systemic toxicity by developing CTX-loaded liposomes modified with ginsenoside Rk1(Rk1/CTX-Lip).Methods:Physical and chemical properties of Rk1/CTX-Lip were investigated.We evaluated the biological functions of Rk1/CTXLip,both in vitro and in vivo.A subcutaneous prostate cancer(RM-1)-bearing mouse model was established to study the efficacy of Rk1/CTX-Lip inhibition in tumors.Simultaneously,a Candida albicans infection model was established in tumor-bearing mice to study the infection-relieving efficacy of Rk1/CTX-Lip.Finally,biocompatibility and in vivo safety of Rk1/CTX-Lip were evaluated.Results:We successfully prepared Rk1/CTX-Lip,achieving high CTX encapsulation efficiency(97.24±0.75)%and physical stability.Rk1/CTX-Lip demonstrated evasion of macrophage phagocytosis,effective tumor tissue targeting,and a significant reduction(>50%)in average tumor volume compared with Chol/CTX-Lip.Moreover,it relieved the concurrent infection burden and effectively regulated immune organs and cells,demonstrating superior biocompatibility.Conclusion:Rk1/CTX-Lip presents a promising new therapy for prostate cancer and holds potential for relieving concurrent fungal infections in cancer patients with low immunity.展开更多
目的验证脂质体药物在心肌缺血区域的炎症靶向效应,探讨其减少心肌细胞缺血再灌注损伤的治疗优势。方法采用薄膜分散-超声-膜挤出法制备胺碘酮及丙酮酸乙酯(EP)脂质体,并对其进行粒径、包封率检查。通过阻断和恢复冠状动脉血流制备大鼠...目的验证脂质体药物在心肌缺血区域的炎症靶向效应,探讨其减少心肌细胞缺血再灌注损伤的治疗优势。方法采用薄膜分散-超声-膜挤出法制备胺碘酮及丙酮酸乙酯(EP)脂质体,并对其进行粒径、包封率检查。通过阻断和恢复冠状动脉血流制备大鼠心肌缺血再灌注损伤(MI-RI)模型,并通过缺血再灌注(I-R)前后心电图变化验证模型。尾静脉给药,考察荧光脂质体在I-R心肌中的炎症靶向效性;取24只SD大鼠(随机分为4组,每组6只),考察胺碘酮脂质体对MI-RI心律失常事件的影响;另取24只SD大鼠(随机分为4组,每组6只),评估丙酮酸乙酯(EP)脂质体对MI-RI中凋亡蛋白Bax,Bcl-2和caspase-3表达水平的影响。结果制备的脂质体药物粒径均匀,制备后24 h内药物渗漏不高于18%。在大鼠心肌I-R后可见心电图ST段及T波的缺血性动态演变,再灌注后心电图记录到了室性心动过速事件,其中I-R+胺碘酮脂质体组心律失常评分明显降低,(P<0.01),且低于胺碘酮溶液组(1.5±0.96 vs 3.0±0.82,P<0.05)。离体荧光成像显示,I-R+IR-775脂质体组荧光强度最高,即荧光脂质体药物可以靶向聚集到心肌缺血部位。与I-R+空白脂质体组和I-R+EP溶液组相比,I-R+EP脂质体组在48 h后显著降低了Bax和caspase-3蛋白表达水平,提高了Bcl-2蛋白的表达,Bax/Bcl-2比值明显下降(P<0.05)。结论脂质体药物在MI-RI中具有显著的炎症靶向效应,脂质体载药结构增强了胺碘酮和EP对MI-RI的治疗效果。展开更多
基金supported by the National Natural Science Foundation of China(82373808)Chongqing Natural Science Foundation(cstc2021jcyj-bshX0125)+1 种基金Fundamental Research Funds for the Central Universities(SWURC2020001)the project for Chongqing University Innovation Research Group,Chongqing Education Committee(CXQT20006).
文摘Objective:In this study,we aim to enhance the anti-prostate cancer efficacy of cabazitaxel(CTX)and reduce its immunosuppression and systemic toxicity by developing CTX-loaded liposomes modified with ginsenoside Rk1(Rk1/CTX-Lip).Methods:Physical and chemical properties of Rk1/CTX-Lip were investigated.We evaluated the biological functions of Rk1/CTXLip,both in vitro and in vivo.A subcutaneous prostate cancer(RM-1)-bearing mouse model was established to study the efficacy of Rk1/CTX-Lip inhibition in tumors.Simultaneously,a Candida albicans infection model was established in tumor-bearing mice to study the infection-relieving efficacy of Rk1/CTX-Lip.Finally,biocompatibility and in vivo safety of Rk1/CTX-Lip were evaluated.Results:We successfully prepared Rk1/CTX-Lip,achieving high CTX encapsulation efficiency(97.24±0.75)%and physical stability.Rk1/CTX-Lip demonstrated evasion of macrophage phagocytosis,effective tumor tissue targeting,and a significant reduction(>50%)in average tumor volume compared with Chol/CTX-Lip.Moreover,it relieved the concurrent infection burden and effectively regulated immune organs and cells,demonstrating superior biocompatibility.Conclusion:Rk1/CTX-Lip presents a promising new therapy for prostate cancer and holds potential for relieving concurrent fungal infections in cancer patients with low immunity.
文摘目的验证脂质体药物在心肌缺血区域的炎症靶向效应,探讨其减少心肌细胞缺血再灌注损伤的治疗优势。方法采用薄膜分散-超声-膜挤出法制备胺碘酮及丙酮酸乙酯(EP)脂质体,并对其进行粒径、包封率检查。通过阻断和恢复冠状动脉血流制备大鼠心肌缺血再灌注损伤(MI-RI)模型,并通过缺血再灌注(I-R)前后心电图变化验证模型。尾静脉给药,考察荧光脂质体在I-R心肌中的炎症靶向效性;取24只SD大鼠(随机分为4组,每组6只),考察胺碘酮脂质体对MI-RI心律失常事件的影响;另取24只SD大鼠(随机分为4组,每组6只),评估丙酮酸乙酯(EP)脂质体对MI-RI中凋亡蛋白Bax,Bcl-2和caspase-3表达水平的影响。结果制备的脂质体药物粒径均匀,制备后24 h内药物渗漏不高于18%。在大鼠心肌I-R后可见心电图ST段及T波的缺血性动态演变,再灌注后心电图记录到了室性心动过速事件,其中I-R+胺碘酮脂质体组心律失常评分明显降低,(P<0.01),且低于胺碘酮溶液组(1.5±0.96 vs 3.0±0.82,P<0.05)。离体荧光成像显示,I-R+IR-775脂质体组荧光强度最高,即荧光脂质体药物可以靶向聚集到心肌缺血部位。与I-R+空白脂质体组和I-R+EP溶液组相比,I-R+EP脂质体组在48 h后显著降低了Bax和caspase-3蛋白表达水平,提高了Bcl-2蛋白的表达,Bax/Bcl-2比值明显下降(P<0.05)。结论脂质体药物在MI-RI中具有显著的炎症靶向效应,脂质体载药结构增强了胺碘酮和EP对MI-RI的治疗效果。
